Učitavanje...

 RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Oronsky, Bryan, Carter, Corey A., Caroen, Scott, Scribner, Curtis, Oronsky, Arnold, Reid, Tony R.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2020
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790525/
https://ncbi.nlm.nih.gov/pubmed/33457091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1746172
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!